{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:40:22Z","timestamp":1793313622212,"version":"4.5.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100632"],"award-info":[{"award-number":["82100632"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2022YFS0633"],"award-info":[{"award-number":["2022YFS0633"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019971","name":"Luzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2021LZXNYD-J09"],"award-info":[{"award-number":["2021LZXNYD-J09"]}],"id":[{"id":"10.13039\/501100019971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Patients with inflammatory bowel disease may develop infective pneumonia after using tumor necrosis factor-\u03b1 inhibitors(TNFis). Due to the limitations of clinical trials, the occurrence of infective pneumonia in patients with inflammatory bowel disease using tumor necrosis factor-\u03b1(TNF-\u03b1) inhibitors remains uncertain. This article primarily explores the relationship between TNF-\u03b1 inhibitors and adverse events(AEs) related to infective pneumonia in the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We collected data from the FAERS database, extracting reports for each TNF-\u03b1 inhibitor from their market launch until the first quarter of 2024 (infliximab, adalimumab, certolizumab pegol, and golimumab) and assessing infective pneumonia associated with TNF-\u03b1 inhibitors using disproportionality analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>After removing duplicate reports, a total of 7176 reports were included. Infliximab and adalimumab exhibited the highest incidence of infective pneumonia-related adverse events, occurring in 3,858 and 2,819 cases, respectively, whereas certolizumab pegol and golimumab showed lower incidences with only 297 and 202 cases. Infliximab had the most positive signals, totaling 10, including tuberculosis, pulmonary tuberculosis, pneumocystis jirovecii pneumonia, histoplasmosis, pneumonia bacterial, pneumonia legionella, bronchopulmonary aspergillosis, tuberculous pleurisy, pneumonia cryptococcal, blastomycosis. Golimumab had seven positive signals, including pneumonia, tuberculosis, pulmonary tuberculosis, bronchopulmonary aspergillosis, pneumonia legionella, pneumonia bacterial, and COVID-19 pneumonia. Certolizumab pegol had only two positive signals: pneumonia and pneumonia klebsiella. However, adalimumab did not show signals of infective pneumonia.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Except for adalimumab, the other three TNF-\u03b1 inhibitors showed positive signals related to infective pneumonia, with tuberculosis-related diseases being the most common. Our study provides important insights for healthcare professionals, which can help reduce the occurrence of infective pneumonia associated with TNF-\u03b1 inhibitors.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0317242","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:31:58Z","timestamp":1754415118000},"page":"e0317242","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Infective pneumonia following the use of tumor necrosis factor-\u03b1 inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1371","volume":"20","author":[{"given":"Qinhui","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-2491","authenticated-orcid":true,"given":"Xiaolin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"pone.0317242.ref001","first-page":"13","article-title":"Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations","volume":"14","author":"RH He","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"pone.0317242.ref002","doi-asserted-by":"crossref","unstructured":"Chang JT. Pathophysiology of Inflammatory Bowel DiseasesJ. New England Journal of Medicine, 2020, 383(27): 2652\u201364.","DOI":"10.1056\/NEJMra2002697"},{"issue":"5","key":"pone.0317242.ref003","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"MF Neurath","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"29","key":"pone.0317242.ref004","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.3748\/wjg.v29.i29.4481","article-title":"Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review","volume":"29","author":"L-F Wang","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"6","key":"pone.0317242.ref005","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/1060028018754896","article-title":"Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-\u03b1 Antagonists","volume":"52","author":"SM McConachie","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"6","key":"pone.0317242.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.02.009","article-title":"Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases","volume":"18","author":"L Beaugerie","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"pone.0317242.ref007","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2022.01.013","article-title":"Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor \u03b1 Antagonists in Inflammatory Bowel Diseases","volume":"20","author":"D Cheng","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0317242.ref008","doi-asserted-by":"crossref","first-page":"980868","DOI":"10.3389\/fcimb.2022.980868","article-title":"Increased susceptibility to pneumonia due to tumour necrosis factor inhibition and prospective immune system rescue via immunotherapy","volume":"12","author":"R Ha","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"9","key":"pone.0317242.ref009","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"RS Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"10114","key":"pone.0317242.ref010","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"SC Ng","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"pone.0317242.ref011","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib","volume":"12","author":"Y Yin","year":"2022","journal-title":"Scientific Reports"},{"issue":"3","key":"pone.0317242.ref012","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11096-022-01397-5","article-title":"A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data","volume":"44","author":"C Wei","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"pone.0317242.ref013","doi-asserted-by":"crossref","unstructured":"Ma JL, Cai JF, Chen H, et al. Cardiovascular Adverse Events Associated with Tumor Necrosis Factor -Alpha Inhibitors: A Real-World Pharmacovigilance AnalysisJ. Journal of Atherosclerosis and Thrombosis, 2024: 15.","DOI":"10.5551\/jat.64767"},{"key":"pone.0317242.ref014","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System","volume":"14","author":"Y Shu","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"1","key":"pone.0317242.ref015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2005.02143.x","article-title":"The intriguing biology of the tumour necrosis factor\/tumour necrosis factor receptor superfamily: players, rules and the games","volume":"115","author":"T Hehlgans","year":"2005","journal-title":"Immunology"},{"issue":"7","key":"pone.0317242.ref016","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/gutjnl-2019-320022","article-title":"25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future","volume":"70","author":"GR D\u2019Haens","year":"2021","journal-title":"Gut"},{"issue":"2","key":"pone.0317242.ref017","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","article-title":"Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics","volume":"16","author":"Y-M Chiu","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"pone.0317242.ref018","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14740338.2019.1577817","article-title":"Update upon the infection risk in patients receiving TNF alpha inhibitors","volume":"18","author":"G Murdaca","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"15","key":"pone.0317242.ref019","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"J Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"pone.0317242.ref020","first-page":"141","article-title":"Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors","volume":"8","author":"T Tanaka","year":"2014","journal-title":"Biologics"},{"issue":"3","key":"pone.0317242.ref021","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/mi.2011.13","article-title":"Role of innate cytokines in mycobacterial infection","volume":"4","author":"AM Cooper","year":"2011","journal-title":"Mucosal Immunol"},{"key":"pone.0317242.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.07.001","article-title":"Recent advances in the treatment of IBD: Targets, mechanisms and related therapies","author":"J Liu","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"pone.0317242.ref023","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","article-title":"Effect of IBD medications on COVID-19 outcomes: results from an international registry","volume":"70","author":"RC Ungaro","year":"2021","journal-title":"Gut"},{"issue":"11","key":"pone.0317242.ref024","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"A Nesbitt","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"pone.0317242.ref025","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"WG Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0317242.ref026","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/apt.13851","article-title":"Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea","volume":"45","author":"SN Hong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"pone.0317242.ref027","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.02.009","article-title":"Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases","volume":"18","author":"L Beaugerie","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"pone.0317242.ref028","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"M Toruner","year":"2008","journal-title":"Gastroenterology"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:32:11Z","timestamp":1754415131000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317242"}},"subtitle":[],"editor":[{"given":"Vinay","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0317242","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]}}}